Tactic Pharma Llc Sells 550,229 Shares of Monopar Therapeutics (NASDAQ:MNPR) Stock

Monopar Therapeutics Inc. (NASDAQ:MNPR) major shareholder Tactic Pharma Llc sold 550,229 shares of the stock in a transaction on Wednesday, September 24th. The stock was sold at an average price of $63.61, for a total value of $35,000,066.69. Following the completion of the sale, the insider owned 272,026 shares in the company, valued at $17,303,573.86. This trade represents a 66.92% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Large shareholders that own more than 10% of a company’s shares are required to disclose their sales and purchases with the SEC.

Monopar Therapeutics Stock Down 1.0%

NASDAQ MNPR opened at $76.63 on Friday. The stock’s 50-day simple moving average is $44.46 and its two-hundred day simple moving average is $39.43. Monopar Therapeutics Inc. has a twelve month low of $4.50 and a twelve month high of $79.80. The company has a market capitalization of $472.81 million, a price-to-earnings ratio of -23.01 and a beta of 1.20.

Monopar Therapeutics (NASDAQ:MNPR) last released its quarterly earnings results on Tuesday, August 12th. The company reported ($0.35) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.47) by $0.12. On average, equities analysts expect that Monopar Therapeutics Inc. will post -1.65 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of equities research analysts have weighed in on the company. HC Wainwright assumed coverage on Monopar Therapeutics in a research report on Tuesday, August 26th. They set a “buy” rating and a $70.00 price target on the stock. Piper Sandler set a $95.00 price target on Monopar Therapeutics and gave the company an “overweight” rating in a research report on Thursday. BTIG Research lifted their price objective on Monopar Therapeutics from $87.00 to $104.00 and gave the stock a “buy” rating in a report on Thursday. Oppenheimer began coverage on Monopar Therapeutics in a report on Wednesday, September 3rd. They issued an “outperform” rating and a $77.00 price objective on the stock. Finally, Cantor Fitzgerald reiterated an “overweight” rating on shares of Monopar Therapeutics in a report on Wednesday. One analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating and one has issued a Hold rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of “Buy” and a consensus target price of $82.33.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the stock. AlphaQuest LLC grew its stake in shares of Monopar Therapeutics by 46.8% in the second quarter. AlphaQuest LLC now owns 1,784 shares of the company’s stock worth $64,000 after purchasing an additional 569 shares during the last quarter. Police & Firemen s Retirement System of New Jersey bought a new stake in shares of Monopar Therapeutics in the second quarter worth about $34,000. JPMorgan Chase & Co. grew its stake in shares of Monopar Therapeutics by 1,821.0% in the second quarter. JPMorgan Chase & Co. now owns 1,921 shares of the company’s stock worth $69,000 after purchasing an additional 1,821 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. bought a new stake in shares of Monopar Therapeutics in the second quarter worth about $80,000. Finally, New York State Common Retirement Fund bought a new stake in shares of Monopar Therapeutics in the second quarter worth about $104,000. Hedge funds and other institutional investors own 1.83% of the company’s stock.

Monopar Therapeutics Company Profile

Monopar Therapeutics Inc, a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. Its lead product candidate in development is Validive, a clonidine hydrochloride mucobuccal tablet that is in Phase 2b/3 clinical trial for the prevention of chemoradiotherapy induced severe oral mucositis in patients with oropharyngeal cancer.